TWST Twist Bioscience Corporation

QT68

Latest market price

152.78

-20.67-11.92%

Overview Short InterestFilings

TWSTQT68Twist Bioscience Corporation·NASDAQ

Overview Short InterestFilings

152.78-11.92%

News

Down 11.9% — Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells (seekingalpha.com).

Medium confidence

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

MDGL-0.31%$430.36 KRYS+2.38%$332.29 PCVX-0.93%$62.03 CAI-5.01%$34.33 KYMR+3.29%$126.63 PTGX+0.35%$144.85 TGTX+5.34%$61.18 TXG-14.03%$70.11

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.22	Insider Own	3.94%	Shs Outstand	65.83M	Perf Week	9.19%

Market Cap	10.06B	Forward P/E	—	EPS next Y	-0.87	Insider Trans	-39.06%	Shs Float	61.89M	Perf Month	-18.76%

Enterprise Value	9.98B	PEG	—	EPS next Q	-0.39			Short Float	16.49%	Perf Quarter	51.18%

Income	-137.00M	P/S	23.28	EPS this Y	—			Short Ratio	4.72	Perf Half Y	152.95%

Sales	432.00M	P/B	22.55	EPS next Y	—	ROA	-20.33%	Short Interest	10.21M	Perf YTD	381.65%

Book/sh	6.77	P/C	60.23	EPS next 5Y	—	ROE	-29.89%	52W High	219.70 -30.46%	Perf Year	374.32%

Cash/sh	2.54	P/FCF	—	EPS past 3/5Y	—	ROIC	-24.57%	52W Low	23.30 555.71%	Perf 3Y	897.26%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	22.72% 33.17%	Gross Margin	51.97%	Volatility	9.93% 9.95%	Perf 5Y	30.13%

Dividend TTM	—	EV/Sales	23.11	EPS Y/Y TTM	—	Oper. Margin	-31.91%	ATR (14)	15.03	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	2.38	Sales Y/Y TTM	19.01%	Profit Margin	-31.66%	RSI (14)	49.24	Recom	2.40

Dividend Gr. 3/5Y	—	Current Ratio	2.67	EPS Q/Q	-7.58%	SMA20	-0.79%	Beta	2.20	Target Price	153.70

Payout	0.00%	Debt/Eq	0.21	Sales Q/Q	22.92%	SMA50	-0.21%	Rel Volume	1.46	Prev Close	173.45

Employees	979	LT Debt/Eq	0.19	Earnings	Nov 12	SMA200	71.63%	Avg Volume	2.32M	Price	152.78

IPO Date	Oct 31, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-48.72% 2.85%	Net Debt/EBITDA	—	Volume	3,396,494	Change	-11.92%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-12-26	Reiterated	Canaccord Genuity	Buy	$120 → $205
Oct-08-26	Reiterated	Jefferies		$150
Oct-07-26	Reiterated	Barclays	Overweight	$95 → $215
Oct-01-26	Reiterated	Guggenheim	Buy	$107 → $212
Sep-29-26	Reiterated	Leerink Partners	Outperform	$160 → $190
Sep-17-26	Reiterated	Leerink Partners	Outperform	$110 → $160
Sep-09-26	Initiated	UBS	Neutral	$89 → $144
Aug-05-26	Reiterated	Piper Sandler	Overweight	$85 → $115
Aug-04-26	Reiterated	Robert W. Baird		$113 → $115
Jul-16-26	Reiterated	Leerink Partners	Outperform	$80 → $110

Latest News· Times ET

Oct-29-26

Oct-29-2608:50PM

Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sellsseekingalpha.com

11:05AM

Parnassus Mid Cap Growth Fund: Q3 2026 Performance Reviewseekingalpha.com

08:00AM

Twist Bioscience Launches MRD Express with Rapid Turnaround Timebusinesswire.com

Oct-28-26

Oct-28-2602:34PM

Twist Bioscience Soars 12%, 10x Genomics Up 12% as Genomics Stocks ReboundYahoo

08:00AM

Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodiesbusinesswire.com

06:50AM

Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractorsseekingalpha.com

Oct-27-26

Oct-27-2602:20AM

Artisan Mid Cap Fund Q3 2026 Portfolio Updateseekingalpha.com

Oct-23-26

Oct-23-2602:23PM

Alger Small Cap Focus Fund Q3 2026 Portfolio Updateseekingalpha.com

Oct-22-26

Oct-22-2604:33PM

Twist Bioscience Sinks 9%, Illumina Down 5% as AI and Genomics Stocks SlideYahoo

05:30AM

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?fool.com

Oct-18-26

Oct-18-2602:21AM

Twist Bioscience (NASDAQ:TWST) Shares Down 7.4% – Here’s Whydefenseworld.net

Oct-15-26

Oct-15-2605:00AM

Polen 5Perspectives Small-Mid Growth Q3 2026 Portfolio Updateseekingalpha.com

01:04AM

How To Invest In AI Drug DiscoverySeekingAlpha

Oct-14-26

Oct-14-2607:58AM

How to Invest in AI Drug Discoveryetftrends.com

Oct-12-26

Oct-12-2604:44AM

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?fool.com

Company

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 9/30/2025	FY 2024 9/30/2024	FY 2023 9/30/2023	FY 2022 9/30/2022	FY 2021 9/30/2021	FY 2020 9/30/2020	FY 2019 9/30/2019	FY 2018 9/30/2018
Total Revenue	432	377	313	245	—	—	—	—	—
Cost of Goods Sold Incl. D&A	208	186	180	155	—	—	—	—	—
Gross Profit	224	191	133	90	—	—	—	—	—
Selling, General and Administrative Excl. Other	291	247	218	190	—	—	—	—	—
Research and Development	72	80	91	107	—	—	—	—	—
Other Operating Expense	0	0	45	10	—	—	—	—	—
Operating Income	-138	-136	-221	-217	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	3	59	13	14	—	—	—	—	—
Net Income Before Taxes	-136	-77	-208	-203	—	—	—	—	—
Income Taxes	0	1	1	1	—	—	—	—	—
Consolidated Net Income	-137	-78	-209	-205	—	—	—	—	—
Net Income From Continuing Operations	-136	-78	-209	-205	—	—	—	—	—
Net Income	-137	-78	-209	-205	—	—	—	—	—
EPS (Recurring)	-2.22	-1.30	-3.60	-3.60	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.22	-1.30	-3.60	-3.60	—	—	—	—	—
EPS (Diluted)	-2.22	-1.30	-3.60	-3.60	—	—	—	—	—
EBITDA	-108	-52	-177	-174	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	21.93	4.48	8.37	4.71	—	—	—	—	—
Gross Margin	51.85	50.66	42.49	36.73	—	—	—	—	—
Operating Margin	-31.94	-36.07	-70.61	-88.57	—	—	—	—	—
Net Margin	-31.71	-20.69	-66.77	-83.67	—	—	—	—	—
Shares Outstanding	62	60	58	57	—	—	—	—	—
Market Capitalization	9,472	1,688	2,620	1,155	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Finn Patrick John	President and COO	Oct 23 '26	Sale	134.59	2,245	302,152	182,843	Oct 27
Laponis Adam	Chief Financial Officer	Oct 09 '26	Sale	156.30	2,462	384,823	98,114	Oct 13
Leproust Emily M.	Chief Executive Officer	Oct 05 '26	Sale	202.15	4,548	919,374	562,760	Oct 07
Cho Dennis	Officer	Oct 02 '26	Sale	188.88	9,514	1,797,042	63,789	Oct 05
Laponis Adam	Chief Financial Officer	Oct 02 '26	Sale	188.88	8,057	1,521,838	100,576	Oct 05
Green Paula	SVP of Human Resources	Oct 02 '26	Sale	188.88	10,088	1,905,462	106,632	Oct 05
Finn Patrick John	President and COO	Oct 02 '26	Sale	188.88	25,714	4,856,963	185,088	Oct 05
Leproust Emily M.	Chief Executive Officer	Oct 02 '26	Sale	188.88	45,736	8,638,799	567,308	Oct 05
WERNER ROBERT F.	Chief Accounting Officer	Oct 02 '26	Sale	188.88	1,482	279,926	42,917	Oct 05
Leproust Emily M.	Chief Executive Officer	Oct 01 '26	Sale	200.00	655	131,000	613,044	Oct 05
Leproust Emily M.	Chief Executive Officer	Sep 24 '26	Sale	177.38	5,203	922,906	613,699	Sep 25
Cho Dennis	Officer	Sep 21 '26	Sale	165.49	348	57,591	73,303	Sep 23
Green Paula	SVP of Human Resources	Sep 21 '26	Sale	165.49	294	48,654	116,720	Sep 23
Leproust Emily M.	Chief Executive Officer	Sep 21 '26	Sale	165.49	1,687	279,183	618,902	Sep 23
Leproust Emily M.	Chief Executive Officer	Sep 17 '26	Option Exercise	20.21	208,708	4,218,324	977,135	Sep 21

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.